Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — UBS 13th Annual Global Life Sciences Conference 2011
35 slides from Biolase's conference presentation, Sep 21, 2011
Slide 1: UBS 13th Annual Global Life Sciences Conference
Exhibit 99.1 UBS 13 Annual Global Life Sciences Conference th September 19-21, 2011, New York City BIOLASE Technology, Inc. Federico Pignatelli, Chairman, CEO & President NASDAQ: BLTI www.biolase.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “e
Slide 3: Market Data
Market Data As of September 15, 2011: Share price……………….....………………………...…………...................................................................... $3.53 Shares issued and outstanding……………………………………………..…..….….....….…………… 30,300,000 Public float (shares held by others than the CEO and Board).…………………..
Slide 4: Financial Highlights
Financial Highlights Turnaround: FortheninemonthperiodendedJune30,2011,BIOLASE generatednon-GAAP netincome of approximately $885,000, as compared to a non-GAAP net loss of approximately $9.3 million for the nine month period ended June 30, 2010. Insider Purchases: During 2011, officers and directors
Slide 5: BIOLASE is About Revolutionizing Surgery in Dentistry and Medicine
BIOLASE is About Revolutionizing Surgery in DentistryandMedicine New management is transforming BIOLASE from a one product, one segment company of the past to a multi-productandmulti-segment platformcompanythatwillbebetterdiversifiedin2012andbeyondand betterpositionedforsubstantialgrowthcomparedtoth
Slide 6: How has BIOLASE Revolutionized Surgery?
HowhasBIOLASE Revolutionized Surgery? …through thescienceofWaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG (2796nm) lase
Slide 7: Why BIOLASE WaterLase Technology in Dentistry?
WhyBIOLASE WaterLase Technology inDentistry? Traditional high-speed drillsworkbyFRICTION whichcreatesHEATwhichcausesPAIN. This PAINnecessitates injections of ANESTHESIA which results inNUMB PAIN and LIPS. In addition, the lack of feeling from the numbing injections can lead to THERMAL DAMAGE which c
Slide 8: Traditional Dentistry
Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 8
Slide 9: Alternative and Advanced Hi-Tech Dentistry
Alternative and Advanced Hi-Tech Dentistry Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System: The iPlus features an The aiming beam on intuitive, touch-based the NEW WaterLase computer screen, iPlus is green. This similar to a tablet red beam featured in personal computer. th
Slide 10: Alternative Dentistry is Less Frightening
Alternative Dentistry is Less Frightening Usingthedentaldrilloffersmoreof thesamewhichispain,localanesthetic, swelling,painkillers,micro- fracturesandcrosscontamination. WaterLasetechnology offersa biologicalsolutionwithnoneofthedownsides of traditional dentistry:NO drill, NO shot, NO pain, and NO c
Slide 11: WaterLase's Amazing Return on Investment
WaterLase’s AmazingReturnonInvestment Monthly Lease Payment New Monthly Revenue Generated Approx. $1,000 $5,000– $15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or WaterLase dentists, for example: • Gingivectomy = $160 •
Slide 12: Technology Supported by Scientific Data
Technology Supported by Scientific Data Substantial Data: • The effectiveness of dental lasers is proven and well researched. • Clinical data and peer- reviewed specialty journals substantiate the effectiveness of laser treatment in a wide variety of procedures. PAGE 12
Slide 13: Dental Schools Teaching WaterLase Technology around the World
Some of the Dental Schools that are Teaching WaterLase Technology around the World PAGE 13
Slide 14: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 14
Slide 15: WaterLase vs. Drill
WaterLase vs. Drill BIOLASE BIOLASE
Slide 16: Patients Urged to Ask Dentists About Risk of Cross Contamination
Warning:Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Studies indicate that cross contamination is a huge 1,2,3,4 threat : • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the abilit
Slide 17: WaterLase Eliminates the Risk of Cross Contamination and Contagion
WaterLase Laser Technology Eliminates the Risk of Cross Contamination and Contagion Because NO Pain, NO Tissue Damage & NO Risk of Cross-Contamination: Burs and Endo Files: WaterLase Tips:WaterLase MD™ reduced E. faecalis 2.86 times more effectively than NaOCl³ • 15%of “sterilized”bursandupto76%of •
Slide 18: Intellectual Property
Intellectual Property Award winning IP: • Recognized for innovation, leadership, and the development of numerous disruptive technologies, most notably the development of a new surgical system to cut human tissue in a biological and atraumatic way. • Received Astrum Award at MDB Capital’s 2011 Bright
Slide 19: Patent Portfolio
Patent Portfolio CurrentStatus:BIOLASEcurrentlyhas279issuedandpendingpatents,70%of whicharerelatedtoour core Er;Cr:YSGG technology and medical lasers. Issued Pending Total U.S. 84 46 130 International 74 75 149 Total 158 122 279 Filingcostsandmaintenance arecloselymonitored.Fundingforredundant paten
Slide 20: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dentallasers:Ourall-tissuelasersincludeournewflagshiplaser,therevolutionary WaterLase iPlus,andtheWaterLase MDTurbo. Diodesoft-tissue dentallasers:OursofttissuelasersincludetheezLasetotaldiode solution,whichofferspowerandportability,andtherevolutionary iLa
Slide 21: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for Home Use • BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license agreement with The Proctor and Gamble Company (“P&G”). • Research indicates that a laser toothbrush for home-use
Slide 22: Further Opportunities to Expand in Medicine
Further Opportunities to Expand in Medicine Withourpatented WaterLase anddiodetechnologies,wehavecreatedtechnological platforms thathavetheabilitytoextendfaroutsideofdentistry.Thisexpansionintonew marketsisa fundamental effortwithinBIOLASE.Weexpecttogreatlyexpandour addressable marketsinthecomingyea
Slide 23: Further Opportunities to Expand in Medicine (Continued)
Further Opportunities to Expand in Medicine (Continued) Podiatry: WehavefoundthatourDiolase10technology isveryeffectiveinthetreatmentofnailfungusandwe arecompleting theclinicalandregulatory requirements necessary toenterthemarket. Orthopedics: Weareworkingwithseveralkeymanufacturers anduniversities
Slide 24: Foundation for a Successful Recovery
Foundation for a Successful Recovery How BIOLASE is positioned for a successful turnaround: • BIOLASE has a better organizational structure, better cost control, and more efficient & effective management than ever before. • The BIOLASE brand is currently known by over 80% of North American dentists
Slide 25: How BIOLASE is Positioned in the Dental Market
How BIOLASE is Positioned in the Dental Market BIOLASE United States BIOLASE International 5,700 2,700 6,800 2,800 Total: 12,500 Total: 5,500 Grand Total: 18,000 PAGE 25
Slide 26: Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market
Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market… Biolase 80% Source: Biolase Technology Licensing Reports PAGE 26
Slide 27: ...and the Overall Dental Laser Market
…and the Overall Dental Laser Market. 2009 US Dental Laser Market: Hard & Soft Tissue Biolase 45% Source: iData Research Inc. PAGE 27
Slide 28: Our Market Opportunity in Dentistry
Our Market Opportunity in Dentistry BIOLASE’s global market opportunity is tremendous! Our current market penetration is approximately 3% in the United States and slightly less than 1% internationally! 1 • 176,000dentistsin theUSandCanada. 2 • Over1.2milliondentistsin134countries. • 18,000 systems i
Slide 29: Incredible Opportunity in Emerging Markets
Incredible Opportunity in Emerging Markets 1 Practicing Dentists Western Europe Eastern Europe 240,000dentists 120,000dentists 1 dentist / 1,800 population 1 dentist / 4,000 population China North America 16,000 dentists 176,000 dentists Middle East 1 dentist / 82,300 population 1 dentist / 1,900 po
Slide 30: BIOLASE Technology, Inc. Today
BIOLASE Technology, Inc. Today BIOLASE is the Global Leader in Dental Lasers: • Over 18,000 laser systems sold to over 11,000 dental practices in over 50 countries worldwide. • We have over 170 employees worldwide • We also have training facilities in Charlotte, NC, St. Louis, MO, and Irvine, CA. BI
Slide 31: Operations
Operations Manufacturing and Research & Development • Our 57,000 sq. ft. facility houses administrative, sales, marketing, customer care, training, R&D and manufacturing. Our Irvine facility can accommodate growth to $250 million. • We are ISO 9001 certified and FDA GMP with clean room operations. W
Slide 32: Recent Developments
Recent Developments Ophthalmology: In June 2011, BIOLASE entered into an agreement with Daniel S. Durrie, M.D., an internationally recognized refractive surgeon, to serve as BIOLASE’s primary ophthalmic expert resource and partnerwithmanagement tooverseethedevelopment andexecutionofourclinicalstudie
Slide 33: Recent Developments (continued)
Recent Developments (continued) LegalSettlement: InJune2011,BIOLASE reacheda finalsettlement withPhilipsElectronics (NYSE:PHG) and Discus Dental LLC, regarding the litigation that Discus brought against BIOLASE in 2010 (Discus was subsequently acquired by Philips). In the litigation, Discus asserted
Slide 34: Chart & Financial History
Chart & Financial History 1994-2006 Pignatelli Aug 2010-Present Exclusive distribution partnership with Pignatelli CEO & Chairman of the Board Henry Schein Aug 2006–Aug 2010Board Chairman 20 15 BLTI SHARE 10 PRICE 1998 FDA Clearance WaterLase 5 1.0 0.5 PAGE 34
Slide 35: UBS 13th Annual Global Life Sciences Conference
UBS 13 Annual Global Life Sciences Conference th September 19-21, 2011, New York City BIOLASE Technology, Inc. Federico Pignatelli, Chairman, CEO&President NASDAQ: BLTI www.biolase.com
Biolase Technology — UBS 13th Annual Global Life Sciences Conference 2011 on 6ix